Journal
FRONTIERS IN MOLECULAR BIOSCIENCES
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmolb.2022.723846
Keywords
CXCL8; tumor microenvironment; tumor progression; tumor immune suppression; immunotherapy
Categories
Funding
- Sichuan International Science and technology innovation cooperation/Hong Kong, Macao
- Taiwan Science and technology innovation cooperation project [2021YFH0172]
- National key research and development program of China [2017YFC0908003]
- National Natural Science Foundation of China [81974099, 81974098]
- Post-doctoral Science Research Foundation of Sichuan University [2020SCU12041]
- National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University [Z2018C01]
- Technology Innovation Research and Development Project, Chengdu Science and Technology Bureau [2021YFH0172, 2019-YF05-00296-SN]
Ask authors/readers for more resources
CXCL8 plays an important role in tumor progression by activating signaling pathways and directly promoting tumor survival. It can also act as a predictive biomarker for immune therapy. Combined blockade of CXCL8 and immune therapy can enhance anti-tumor efficacy.
The chemokine CXCL8 has been found to play an important role in tumor progression in recent years. CXCL8 activates multiple intracellular signaling pathways by binding to its receptors (CXCR1/2), and plays dual pro-tumorigenic roles in the tumor microenvironment (TME) including directly promoting tumor survival and affecting components of TME to indirectly facilitate tumor progression, which include facilitating tumor cell proliferation and epithelial-to-mesenchymal transition (EMT), pro-angiogenesis, and inhibit anti-tumor immunity. More recently, clinical trials indicate that CXCL8 can act as an independently predictive biomarker in patients receiving immune checkpoint inhibitions (ICIs) therapy. Preclinical studies also suggest that combined CXCL8 blockade and ICIs therapy can enhance the anti-tumor efficacy, and several clinical trials are being conducted to evaluate this therapy modality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available